SoQut Imaging is a French « deeptech » startup based in Bordeaux, founded in 2021, that revolutionizes liver disease diagnosis through innovation in medical imaging. Specializing in the early and non-invasive detection of MASH (Metabolic Associated Steatotic Liver Disease, formerly NASH), the company has developed Elibio®, a patented MRI SaaS Software. This solution delivers a « digital liver biopsy, » providing the precision of a traditional biopsy without its drawbacks (risks, costs, or invasive nature of biopsy).

The company finds its roots within University laboratories and fundamental research. Since then, SoQut has developed its DNA around medical product development, to translate R&D developments into clinically applicable technology, and better serve clinicians and patients.

To that end, Soqut gathers a multidisciplinary team, driven by an innovation mindset, with the global aim to democratize access to early diagnosis; and establish itself in clinical and pharmaceutical markets in Europe and the United States by 2027.

SoQut Imaging offers an innovative solution called Elibio®, a SaaS-based medical software integrated into existing MRI systems. This technology enables a “digital liver biopsy” by automatically analyzing medical imaging data.

It provides key indicators such as steatosis, fibrosis, and iron overload, which are essential to diagnose and monitor liver diseases, particularly MASH.

Unlike traditional biopsy, this approach is non-invasive, painless, and risk-free for patients, while also being fast (> 20 seconds MRI acquisition) and integrated into the existing radiological and clinical workflow, ensuring its smooth adoption by physicians.

Designed to assist clinicians and pharmaceutical companies in their drug development and commercialization efforts, Elibio facilitates early diagnosis and treatment monitoring : it is the new « NIT », non-invasive test the community has been waiting for, to improve patient care and sustainably transform the diagnosis of liver diseases.